Last $85.74 USD
Change Today +0.255 / 0.30%
Volume 2.0M
ESRX On Other Exchanges
Symbol
Exchange
ESRX is not on other exchanges.
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

express scripts holding co (ESRX) Key Developments

Express Scripts Holding Company(NasdaqGS:ESRX) added to S&P 500 Growth Index

Express Scripts Holding Company(NasdaqGS:ESRX) added to S&P 500 Growth Index

Express Scripts Holding Company Announces Executive Changes

Express Scripts announced that it is initiating a Chief Financial Officer transition process. Cathy R. Smith will be leaving the company to pursue other interests and no longer serves in the role of Executive Vice President and Chief Financial Officer of the company. Ms. Smith will continue her employment into the first quarter of 2015 in order to facilitate a smooth and orderly transition. The company also announced that James M. Havel has been appointed to serve as Executive Vice President and Interim Chief Financial Officer effective January 2, 2015. Mr. Havel will join Express Scripts from Major Brands Holdings, where he has served as the Chief Financial Officer since April 2012. Previously, Mr. Havel owned and operated Havel Associates, LLC from July 2010 to April 2012.

Express Scripts Reaffirms Earnings Guidance for the Year 2014

Express Scripts reaffirmed earnings guidance for the year 2014. The company is reaffirming its adjusted earnings per diluted share guidance range of $4.86 to $4.90, which maintains the mid-point of $4.88. The guidance range reflects year over year growth of 18% to 19% excluding the impact of the roll-off of UnitedHealth Group claims or growth of 12% to 13%.

Three Pharmacies Suing Express Scripts over Rejected Claims Compounded Drugs for Denying Coverage of Compounded Drugs

Three out-of-state pharmacies are suing Express Scripts Holding Company for denying coverage of compounded drugs. The suit, filed in the U.S. District Court in St. Louis, alleges that Express Scripts is trying to cut costs by denying payments to pharmacies for compounded drugs, which are mixed and prepared at certain pharmacies per a doctor's order. The lawsuit alleges the compound drugs were previously covered, and that denials started occurring this past June. The plaintiffs are Texas-based Annie's Apothecary; Cypress Compounding Pharmacy, also in Texas; and Louisiana-based Mason's Pharmacy.

Express Scripts Mulls Acquisitions

Express Scripts Holding Company (NasdaqGS:ESRX) is seeking acquisitions. Cathy Smith, Chief Financial Officer and Executive Vice President of Express Scripts, said, "The second priority will always be around strategic acquisitions. And the chart I'm going to show you next shows you that we have a great demonstrated track record around strategic acquisitions. Again we're going to be prudent and thoughtful and disciplined, like we always have been, but we'll also remain opportunistic around acquisitions."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ESRX:US $85.74 USD 0.00

ESRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Anthem Inc $126.36 USD -0.57
Cardinal Health Inc $81.84 USD -0.23
McKesson Corp $210.15 USD +0.36
Kroger Co/The $64.29 USD +0.24
Walgreen Co $76.46 USD -0.21
View Industry Companies
 

Industry Analysis

ESRX

Industry Average

Valuation ESRX Industry Range
Price/Earnings 34.3x
Price/Sales 0.6x
Price/Book 3.1x
Price/Cash Flow 16.4x
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXPRESS SCRIPTS HOLDING CO, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.